Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hiba El Sayadi"'
Autor:
Carmela Dantas-Barbosa, Isabelle Ray-Coquard, Tom Lesluyes, Pierre Meeus, Jean-Yves Blay, Antoine Italiano, Pierre Saintigny, Marie-Pierre Sunyach, Hiba El Sayadi, M. Jean-Denis, Mehdi Brahmi, Sylvie Bonvalot, Laurent Alberti, Maud Toulmonde, Axel Le Cesne, Jean-Michel Coindre, Frédéric Chibon, Françoise Ducimetière, Isabelle Treilleux, François Le Loarer, Olivier Mir, Olivia Bally, Dominique Ranchère
Publikováno v:
British Journal of Cancer
Background: Leiomyosarcoma (LMS) are 15% of adult sarcomas and remain seldom curable in metastatic phase. The TAM receptors and their ligands are overexpressed or activated in multiple malignancies, including LMS. Methods: The TAM receptor and ligand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04bdb8cdd802f3d10000293946495b7d
https://doi.org/10.1038/bjc.2017.354
https://doi.org/10.1038/bjc.2017.354
Autor:
Philippe A. Cassier, Jean-Yves Blay, Pierre-Paul Bringuier, Samia Arifi, Isabelle Ray-Coquard, Jean-Yves Scoazec, Armelle Dufresne, Laurent Alberti, Hiba El Sayadi
Publikováno v:
Current Gastroenterology Reports. 10:555-561
Gastrointestinal stromal tumors (GIST) are rare tumors of mesenchymal origin that may arise anywhere along the gastrointestinal tract or in the peritoneum. In most cases, GIST harbor mutations of KIT or PDGFRA. Imatinib mesylate (IM), a small-molecul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d52f11233bc4fc5b4de45e4515543a00
https://doi.org/10.1007/s11894-008-0102-z
https://doi.org/10.1007/s11894-008-0102-z
Autor:
Jean-François Emile, Jean-Philippe Michot, Séverine Tabone-Eglinger, Laurent Alberti, Nathalie Théou-Anton, Antoinette Lemoine, Jean-Yves Blay, Hiba El Sayadi, Eric Tabone, Frédéric Subra
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2008, 14 (8), pp.2285-94. ⟨10.1158/1078-0432.CCR-07-4102⟩
Clinical Cancer Research, American Association for Cancer Research, 2008, 14 (8), pp.2285-94. ⟨10.1158/1078-0432.CCR-07-4102⟩
Purpose: Gastrointestinal stromal tumors (GIST) are frequently associated with gain-of-function mutations of KIT, which can be inhibited by imatinib both in vitro and in vivo. The survival of patients with GIST, following imatinib therapy, has been c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e95a8cdc6127201b3f93aafdf690e27c
https://doi.org/10.1158/1078-0432.ccr-07-4102
https://doi.org/10.1158/1078-0432.ccr-07-4102
Autor:
Philippe A, Cassier, Armelle, Dufresne, Hiba, El Sayadi, Daniel, Pissaloux, Laurent, Alberti, Anne Valérie, Decouvelaere, Dominique, Ranchere, Isabelle, Ray-Coquard, Jean-Yves, Blay
Publikováno v:
Bulletin du cancer. 95(10)
Recent progress made in the field of sarcoma biology has shed new light on the pathophysiology of these numerous but rare diseases. Soft tissue sarcomas can be divided into 6 sub-types based on the underlying molecular biology of the disease: 1) tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0003c24122f866b47e4b5d8d59f2891d
https://pubmed.ncbi.nlm.nih.gov/19004727
https://pubmed.ncbi.nlm.nih.gov/19004727
Autor:
Laurent Alberti, Anne-Valérie Decouvelaere, Jean-Yves Blay, Armelle Dufresne, Intidar Labidi, Samia Arifi, Philippe A. Cassier, Séverine Tabone, Marie-Pierre Sunyach, Hiba El Sayadi, Isabelle Ray-Coquard, Pierre Meeus, Dominique Ranchère
Publikováno v:
Expert opinion on pharmacotherapy. 9(7)
The molecular hallmark of gastrointestinal stromal tumours (GISTs), the mutation of the KIT gene, was discovered 10 years ago. GISTs have since been recognized as separate pathological entities among sarcomas, and have become a model for targeted tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ab3afd0233d277de23e7cd0f79e2a12
https://pubmed.ncbi.nlm.nih.gov/18422477
https://pubmed.ncbi.nlm.nih.gov/18422477
Autor:
Samia, Arifi, Hiba, El Sayadi, Armelle, Dufresne, Isabelle, Ray-Coquard, Jérôme, Fayette, Pierre, Méeus, Dominique, Ranchère, Anne-Valérie, Decouvelaere, Laurent, Alberti, Séverine, Tabone-Eglinger, Jean-Yves, Blay, Philippe, Cassier
Publikováno v:
Bulletin du cancer. 95(1)
Imatinib mesylate (Gleevec, Glivec, Novartis, Basel, Switzerland) is a small molecule inhibitor of the tyrosine kinase c-abl, c-kit and the platelet derived growth factor receptor (PDGFR). Imatinib was developed for the treatment of chronic myeloid l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f1046e3464bf4c70e14b2ad4f77db710
https://pubmed.ncbi.nlm.nih.gov/18230575
https://pubmed.ncbi.nlm.nih.gov/18230575